关注公众号
收藏产品 产品详情
抗体来源（Source）
Biotinylated Anti-Bevacizumab Antibody (AY13) is a mouse monoclonal antibody derived from hybridoma cells fused with SP2/0 myeloma cells and murine B lymphocytes.
抗体类型（Antibody Type）
Hybridoma Monoclonal
克隆号（Clone）
AY13
亚型（Isotype）
Mouse IgG1, Kappa
宿主（Host Species）
Mouse
免疫原（Immunogen）
Bevacizumab
偶联（Conjugate）
Biotin
特异性（Specificity）
Recognizes Bevacizumab specifically.
应用（Application）
ApplicationRecommended UsageELISA1:100-1:1000纯化（Purification）
Protein A purified / Protein G purified.
浓度（Concentration）
Please refer to the Certificate of Analysis (CoA).
产品形式（Form）
Lyophilized
制剂（Formulation）
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4) containing 0.03% PF68, with trehalose as protectant.
Please contact us for customized product forms or formulations.
重构方法（Reconstitution）
Please refer to the Certificate of Analysis (CoA) for specific instructions.
运输（Shipping）
Lyophilized product is shipped at ambient temperature.
存储（Storage）
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
合规声明（Notices）
Product Specific Notices: For research use only.
质量管理控制体系（QMS）
推荐产品
数据展示
活性（Bioactivity）-ELISA
Detection of bevacizumab by bridging ELISA in serum. Immobilized Anti-Bevacizumab Antibody (AY10) (Cat. No. BEB-Y10) at 2 μg/mL, add increasing concentrations of bevacizumab (10% human serum) and then add Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) at 2 μg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 0.4 μg/mL (QC tested).
Protocol
Immobilized bevacizumab at 1 μg/mL (100 μL/well) can bind Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) with a linear range of 0.78-25.5 ng/mL.
Protocol
Serial dilutions of Biotinylated Anti-Bevacizumab Antibody (AY13) (Cat. No. BEB-BY13) were added into Human VEGF165, premium grade (Cat. No. VE5-H4210): Human Anti-VEGFA(AVASTIN), Human IgG1 (D239E, L241M) | Human Kappa binding reactions. The half maximal inhibitory concentration (IC50) is 1.032 μg/mL (Routinely tested).
Protocol
用户评价 发表评论
联系我们 
项目合作 